Yong Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yong Wu has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Pengfei She
Department of Laboratory Medicine, The Third Xiangya Hosipital of Central South University, Changsha, China
35 shared publicationsLinying Zhou
Department of Laboratory Medicine, The First Hospital of Changsha (Affiliated Changsha Hospital of Xiangya, School of Medicine Central South University), Changsha, China
22 shared publicationsYimin Li
The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China
21 shared publicationsShasha Liu
Department of Laboratory Medicine, the third Xiangya Hospital of Central South University, Changsha, China
14 shared publicationsZehao Li
Department of Laboratory Medicine, the third Xiangya Hospital of Central South University, Changsha, China
14 shared publicationsLanlan Xu
Department of Laboratory Medicine, Third Xiangya Hospital of Central South University , Changsha 410005 , China
13 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 23 (1) , 108
Correction: Metagenomic next-generation sequencing for pathogen detection of pulmonary infections in persons living with HIV
- 13 November 2026
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 23 (1) , 108
Open AccessCorrection: Metagenomic next-generation sequencing for pathogen detection of pulmonary infections in persons living with HIV
- 11 November 2026
- Published by Elsevier in Microbiological Research
- Vol. 315, 128820
INE963: A repurposed antiparasitic combating methicillin-resistant Staphylococcus aureus and colistin-resistant Acinetobacter baumannii
- 11 November 2026
- Published by Elsevier in Microbiological Research
- Vol. 315, 128820
INE963: A repurposed antiparasitic combating methicillin-resistant Staphylococcus aureus and colistin-resistant Acinetobacter baumannii
- Open Access
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
INE963: a repurposed antiparasitic combating methicillin-resistant Staphylococcus aureus and colistin-resistant Acinetobacter baumannii
The emergence of multidrug-resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA) and colistin-resistant Acinetobacter baumannii, necessitates novel antibacterial strategies. Via high-throughput screening of an FDA-approved drug library, we identified the antiparasitic small molecule INE963 as a multi-function antibacterial candidate. Against MRSA, INE963 exerted potent bactericidal activity with low resistance propensity. Mechanistically, it targeted phosphatidylglycerol in the bacterial membrane, disrupted the proton motive force and thereby induced energy metabolism disorder and a lethal burst of reactive oxygen species. INE963 also downregulated the Agr quorum sensing system, suppressed biofilm formation and eradicated preformed biofilms. In terms of colistin-resistant A. baumannii, INE963 directly bound to lipopolysaccharide and synergized with colistin to restore bacterial susceptibility, which compromised membrane integrity, depolarized membrane potential, disrupted proton motive force and caused ATP depletion and oxidative stress. In vivo, INE963 monotherapy exhibited robust efficacy in murine models of MRSA-related wound infection, peritonitis and implant-associated osteoarthritis, reducing bacterial loads, accelerating wound healing and preventing bone destruction. The combination of INE963 and colistin was effective in colistin-resistant A. baumannii peritonitis, attenuating systemic bacterial dissemination and tissue pathology. Comprehensive safety assessments confirmed low cytotoxicity and no overt organ toxicity at therapeutic doses. In all, INE963 is a promising multi-function antibacterial agent integrating direct membrane targeting, virulence neutralization and colistin sensitization, providing a novel strategy to combat MRSA and colistin-resistant A. baumannii infections.
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessINE963: a repurposed antiparasitic combating methicillin-resistant Staphylococcus aureus and colistin-resistant Acinetobacter baumannii
The emergence of multidrug-resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA) and colistin-resistant Acinetobacter baumannii, necessitates novel antibacterial strategies. Via high-throughput screening of an FDA-approved drug library, we identified the antiparasitic small molecule INE963 as a multi-function antibacterial candidate. Against MRSA, INE963 exerted potent bactericidal activity with low resistance propensity. Mechanistically, it targeted phosphatidylglycerol in the bacterial membrane, disrupted the proton motive force and thereby induced energy metabolism disorder and a lethal burst of reactive oxygen species. INE963 also downregulated the Agr quorum sensing system, suppressed biofilm formation and eradicated preformed biofilms. In terms of colistin-resistant A. baumannii, INE963 directly bound to lipopolysaccharide and synergized with colistin to restore bacterial susceptibility, which compromised membrane integrity, depolarized membrane potential, disrupted proton motive force and caused ATP depletion and oxidative stress. In vivo, INE963 monotherapy exhibited robust efficacy in murine models of MRSA-related wound infection, peritonitis and implant-associated osteoarthritis, reducing bacterial loads, accelerating wound healing and preventing bone destruction. The combination of INE963 and colistin was effective in colistin-resistant A. baumannii peritonitis, attenuating systemic bacterial dissemination and tissue pathology. Comprehensive safety assessments confirmed low cytotoxicity and no overt organ toxicity at therapeutic doses. In all, INE963 is a promising multi-function antibacterial agent integrating direct membrane targeting, virulence neutralization and colistin sensitization, providing a novel strategy to combat MRSA and colistin-resistant A. baumannii infections.
- Open Access
- 2 July 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Resorantel: a dual-targeting therapeutic with potent efficacy against Staphylococcus aureus with low potential for drug resistance
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a significant public health concern. The biofilm formation capability of MRSA is often associated with high levels of antimicrobial resistance. Therefore, the development of novel therapeutic strategies to combat MRSA is urgently warranted. By drug repurposing, resorantel, originally developed as an antiparasitic agent, has demonstrated significantly bactericidal activity against MRSA and its biofilms with effectively inhibitory activity against the emergence of drug resistance. Furthermore, resorantel displayed significant in vivo antibacterial efficacy in both topic and systemic infection models. Mechanistic investigations employing transcriptomics, fluorescent probes, molecular dynamics simulations, and surface plasmon resonance analysis revealed that proton motive force and MurB are likely the potential targets of resorantel. Collectively, this study identifies resorantel as a promising novel antimicrobial agent with potential for use in the treatment of MRSA and its biofilm-related infections.
- 2 July 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessResorantel: a dual-targeting therapeutic with potent efficacy against Staphylococcus aureus with low potential for drug resistance
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a significant public health concern. The biofilm formation capability of MRSA is often associated with high levels of antimicrobial resistance. Therefore, the development of novel therapeutic strategies to combat MRSA is urgently warranted. By drug repurposing, resorantel, originally developed as an antiparasitic agent, has demonstrated significantly bactericidal activity against MRSA and its biofilms with effectively inhibitory activity against the emergence of drug resistance. Furthermore, resorantel displayed significant in vivo antibacterial efficacy in both topic and systemic infection models. Mechanistic investigations employing transcriptomics, fluorescent probes, molecular dynamics simulations, and surface plasmon resonance analysis revealed that proton motive force and MurB are likely the potential targets of resorantel. Collectively, this study identifies resorantel as a promising novel antimicrobial agent with potential for use in the treatment of MRSA and its biofilm-related infections.
- Open Access
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1851763
Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes
Purpose: Methicillin-resistant Staphylococcus aureus (MRSA) is frequently observed in biofilm form, exhibiting significant tolerance, particularly in the context of deep tissue infections such as osteomyelitis. This characteristic renders clinical treatment extremely challenging. Therefore, the development of novel antibacterial agents against MRSA and its biofilms is identified as an urgent priority. Methods: By drug repurposing, this study determines the antibacterial activity of the anti-amoebic small molecule tiliquinol against MRSA and its highly drug-resistant biofilms and evaluates its potential to induce MRSA resistance. The antibacterial mechanism of tiliquinol is examined utilizing transcriptomics, fluorescent probes, and quantitative reverse-transcription polymerase chain reaction. In addition, we evaluate in vivo antibacterial efficacy and safety profiles by established multiple murine infection models, including skin and soft tissue infection, sepsis, as well as the periprosthetic joint infection. Results: The research find that tiliquinol exhibits notable antibacterial activity against MRSA and its highly resistant biofilms avoiding resistance occurrence. Mechanism study reveals that the proton motive force and peptidoglycan are potential therapeutic targets by tiliquinol. Further, in various mouse infection models, favorable in vivo antibacterial efficacy with satisfied safety profiles of tiliquinol are confirmed. Conclusion: Tiliquinol is recognized as a novel therapeutic strategy against refractory MRSA-related infections, particularly those associated with osteomyelitis and implant-related complications.
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1851763
Open AccessDrug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes
Purpose: Methicillin-resistant Staphylococcus aureus (MRSA) is frequently observed in biofilm form, exhibiting significant tolerance, particularly in the context of deep tissue infections such as osteomyelitis. This characteristic renders clinical treatment extremely challenging. Therefore, the development of novel antibacterial agents against MRSA and its biofilms is identified as an urgent priority. Methods: By drug repurposing, this study determines the antibacterial activity of the anti-amoebic small molecule tiliquinol against MRSA and its highly drug-resistant biofilms and evaluates its potential to induce MRSA resistance. The antibacterial mechanism of tiliquinol is examined utilizing transcriptomics, fluorescent probes, and quantitative reverse-transcription polymerase chain reaction. In addition, we evaluate in vivo antibacterial efficacy and safety profiles by established multiple murine infection models, including skin and soft tissue infection, sepsis, as well as the periprosthetic joint infection. Results: The research find that tiliquinol exhibits notable antibacterial activity against MRSA and its highly resistant biofilms avoiding resistance occurrence. Mechanism study reveals that the proton motive force and peptidoglycan are potential therapeutic targets by tiliquinol. Further, in various mouse infection models, favorable in vivo antibacterial efficacy with satisfied safety profiles of tiliquinol are confirmed. Conclusion: Tiliquinol is recognized as a novel therapeutic strategy against refractory MRSA-related infections, particularly those associated with osteomyelitis and implant-related complications.
- Open Access
- 16 March 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1) , 2646808
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against acinetobacter baumannii
Acinetobacter baumannii is an opportunistic pathogenic Gram-negative bacillus and one of the main pathogens causing hospital-acquired infections. It can cause varied types of infection, including m...
- 16 March 2026
- Published by Taylor & Francis in Virulence
- Vol. 17 (1) , 2646808
Open AccessAntibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against acinetobacter baumannii
Acinetobacter baumannii is an opportunistic pathogenic Gram-negative bacillus and one of the main pathogens causing hospital-acquired infections. It can cause varied types of infection, including m...
- Open Access
- 4 February 2026
- Published by Springer Nature in AMB Express
- Vol. 16 (1)
Repurposed bunamidine disrupts envelope energetics and induces ROS-mediated non-lytic killing
Methicillin-resistant Staphylococcus aureus (MRSA) remains a major public health threat due to its multidrug resistance, biofilm formation, and persistence, which collectively limit the effectiveness of current antibiotics. Here we characterize bunamidine hydrochloride (BUN), a repurposed benzimidazole derivative, as a potent anti-MRSA candidate. Across clinical and reference isolates, BUN displayed low MIC/MBC values (4–8 μg/mL), rapid bactericidal activity, and consistent efficacy in both planktonic and biofilm-associated populations. BUN eradicated persister cells within hours, while exhibiting a markedly reduced propensity for resistance development compared with ciprofloxacin. Mechanistic analyses revealed that BUN disrupts envelope energetics—causing membrane depolarization, collapse of the proton motive force, ATP depletion, and lipid disorder—without pore formation. These events triggered amplification of reactive oxygen species (ROS), which acted as critical execution factors for bacterial killing. Hemolysis assays confirmed selective compatibility with mammalian membranes, consistent with a non-lytic mode of action. In murine abscess and wound infection models, which represent early acute infection stages rather than established biofilm or chronic conditions, topical BUN treatment reduced bacterial burden, accelerated wound closure, and alleviated inflammation without apparent toxicity. These results demonstrate early therapeutic efficacy, tissue-protective, and anti-inflammatory effects in acute infection settings. While the current in vivo models support antibacterial efficacy during early infection, evaluation in established biofilm or chronic infection models will be an important direction for future studies.
- 4 February 2026
- Published by Springer Nature in AMB Express
- Vol. 16 (1)
Open AccessRepurposed bunamidine disrupts envelope energetics and induces ROS-mediated non-lytic killing
Methicillin-resistant Staphylococcus aureus (MRSA) remains a major public health threat due to its multidrug resistance, biofilm formation, and persistence, which collectively limit the effectiveness of current antibiotics. Here we characterize bunamidine hydrochloride (BUN), a repurposed benzimidazole derivative, as a potent anti-MRSA candidate. Across clinical and reference isolates, BUN displayed low MIC/MBC values (4–8 μg/mL), rapid bactericidal activity, and consistent efficacy in both planktonic and biofilm-associated populations. BUN eradicated persister cells within hours, while exhibiting a markedly reduced propensity for resistance development compared with ciprofloxacin. Mechanistic analyses revealed that BUN disrupts envelope energetics—causing membrane depolarization, collapse of the proton motive force, ATP depletion, and lipid disorder—without pore formation. These events triggered amplification of reactive oxygen species (ROS), which acted as critical execution factors for bacterial killing. Hemolysis assays confirmed selective compatibility with mammalian membranes, consistent with a non-lytic mode of action. In murine abscess and wound infection models, which represent early acute infection stages rather than established biofilm or chronic conditions, topical BUN treatment reduced bacterial burden, accelerated wound closure, and alleviated inflammation without apparent toxicity. These results demonstrate early therapeutic efficacy, tissue-protective, and anti-inflammatory effects in acute infection settings. While the current in vivo models support antibacterial efficacy during early infection, evaluation in established biofilm or chronic infection models will be an important direction for future studies.
- Open Access
- 18 November 2025
- Published by American Society for Microbiology in mSystems
- Vol. 10 (11) , e0042525
Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes
Vancomycin-resistant enterococci (VRE) are a major cause of hospital-acquired infections, with limited treatment options due to rising antibiotic resistance. Targeting bacterial membranes offers a promising alternative to conventional therapies. In this study, we investigated the antimicrobial activity and mechanism of action of bunamidine hydrochloride (BUN) against VRE. BUN exhibited potent bactericidal effects against both VRE and vancomycin-susceptible enterococci (VSE), with minimum inhibitory concentrations (MICs) ranging from 2 to 4 µg/mL. BUN significantly inhibited biofilm formation and eradicated biofilm-embedded persister cells. Mechanistic studies demonstrated that BUN disrupts bacterial membrane integrity, increasing permeability and depolarization, as confirmed by SYTOX Green staining, DiSC3(5) fluorescence analysis, and electron microscopy. Molecular dynamics simulations further revealed that BUN selectively interacts with phosphatidylglycerol, a key bacterial membrane phospholipid, leading to membrane destabilization. In vivo studies using murine infection models showed that BUN effectively reduced bacterial burden and promoted wound healing without notable toxicity. These findings highlight BUN as a promising antimicrobial agent with membrane-targeting activity against VRE. Its potent bactericidal action, low propensity for resistance development, and favorable in vivo efficacy suggest potential for therapeutic application in treating multidrug-resistant infections. IMPORTANCE: The global rise of vancomycin-resistant enterococci (VRE) poses serious challenges in clinical treatment due to limited therapeutic options and rapid resistance development. This study identifies bunamidine hydrochloride (BUN), a previously approved antiparasitic agent, as a potent membrane-targeting antimicrobial with rapid bactericidal activity against both planktonic and biofilm-associated VRE. By selectively interacting with bacterial phosphatidylglycerol, BUN disrupts membrane integrity and inhibits persister cells, while maintaining low cytotoxicity and high in vivo efficacy in murine infection models. Our findings highlight the potential of drug repurposing strategies to accelerate the discovery of effective antibiotics and provide a promising candidate for future clinical management of multidrug-resistant bacterial infections.
- 18 November 2025
- Published by American Society for Microbiology in mSystems
- Vol. 10 (11) , e0042525
Open AccessRepurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes
Vancomycin-resistant enterococci (VRE) are a major cause of hospital-acquired infections, with limited treatment options due to rising antibiotic resistance. Targeting bacterial membranes offers a promising alternative to conventional therapies. In this study, we investigated the antimicrobial activity and mechanism of action of bunamidine hydrochloride (BUN) against VRE. BUN exhibited potent bactericidal effects against both VRE and vancomycin-susceptible enterococci (VSE), with minimum inhibitory concentrations (MICs) ranging from 2 to 4 µg/mL. BUN significantly inhibited biofilm formation and eradicated biofilm-embedded persister cells. Mechanistic studies demonstrated that BUN disrupts bacterial membrane integrity, increasing permeability and depolarization, as confirmed by SYTOX Green staining, DiSC3(5) fluorescence analysis, and electron microscopy. Molecular dynamics simulations further revealed that BUN selectively interacts with phosphatidylglycerol, a key bacterial membrane phospholipid, leading to membrane destabilization. In vivo studies using murine infection models showed that BUN effectively reduced bacterial burden and promoted wound healing without notable toxicity. These findings highlight BUN as a promising antimicrobial agent with membrane-targeting activity against VRE. Its potent bactericidal action, low propensity for resistance development, and favorable in vivo efficacy suggest potential for therapeutic application in treating multidrug-resistant infections. IMPORTANCE: The global rise of vancomycin-resistant enterococci (VRE) poses serious challenges in clinical treatment due to limited therapeutic options and rapid resistance development. This study identifies bunamidine hydrochloride (BUN), a previously approved antiparasitic agent, as a potent membrane-targeting antimicrobial with rapid bactericidal activity against both planktonic and biofilm-associated VRE. By selectively interacting with bacterial phosphatidylglycerol, BUN disrupts membrane integrity and inhibits persister cells, while maintaining low cytotoxicity and high in vivo efficacy in murine infection models. Our findings highlight the potential of drug repurposing strategies to accelerate the discovery of effective antibiotics and provide a promising candidate for future clinical management of multidrug-resistant bacterial infections.
- Open Access
- 29 October 2025
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 35 (10) , 1-16
Drug Repurposing: An Emerging Strategy in Staphylococcus aureus Infections
Yimin Li, Pengfei She, Yiqing Liu, Shaowei Guo, Guanqing Huang, Dan Xiao, and Yong Wu. J. Microbiol. Biotechnol. 2025;35:1-16. https://doi.org/10.4014/jmb.2507.07048
- 29 October 2025
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 35 (10) , 1-16
Open AccessDrug Repurposing: An Emerging Strategy in Staphylococcus aureus Infections
Yimin Li, Pengfei She, Yiqing Liu, Shaowei Guo, Guanqing Huang, Dan Xiao, and Yong Wu. J. Microbiol. Biotechnol. 2025;35:1-16. https://doi.org/10.4014/jmb.2507.07048
- Open Access
- 29 September 2025
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-9
Metagenomic next-generation sequencing for pathogen detection of pulmonary infections in persons living with HIV
This study aimed to evaluate the diagnostic utility of metagenomic next-generation sequencing (mNGS) in detecting pulmonary infections in persons living with HIV(PLWH). We conducted a retrospective study involving 246 PLWH with pulmonary infections. Bronchoalveolar lavage fluid (BALF) specimens were collected from all patients. mNGS and traditional microbial cultures were performed in parallel to compare the differences in pathogen identification. Patients were stratified by immune status based on CD4+ T cell counts, and the association between pathogen profiles and immunodeficiency severity was analyzed. mNGS demonstrated a significantly higher pathogen detection sensitivity (98.0%) compared to traditional cultures (32.1%). The spectrum of pathogens detected by mNGS and culture methods differed significantly. mNGS identified 123 pathogenic microorganisms, whereas cultures detected only 17. mNGS detected additional pathogens, including viruses (e.g., Epstein-Barr virus and cytomegalovirus) and fastidious microorganisms (e.g., Pneumocystis jirovecii). Furthermore, mNGS revealed a significant correlation between PLWH-associated immunodeficiency and pathogen profiles. The diversity of pathogens, particularly fungi and viruses, increased with declining CD4+ T cell counts (p < 0.05). mNGS comprehensively characterizes the complex pathogen spectrum in PLWH-associated pulmonary infections, significantly enhancing detection sensitivity for mixed and fastidious infections, thereby guiding targeted anti-infective therapy. Immunosuppression severity strongly correlates with opportunistic pathogen profiles and the risk of specific pathogen detection, highlighting the importance of immune status-guided clinical strategies. mNGS serves as a valuable adjunct to conventional diagnostic methods, enhancing the detection and prognostic assessment of infectious complications in PLWH.
- 29 September 2025
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-9
Open AccessMetagenomic next-generation sequencing for pathogen detection of pulmonary infections in persons living with HIV
This study aimed to evaluate the diagnostic utility of metagenomic next-generation sequencing (mNGS) in detecting pulmonary infections in persons living with HIV(PLWH). We conducted a retrospective study involving 246 PLWH with pulmonary infections. Bronchoalveolar lavage fluid (BALF) specimens were collected from all patients. mNGS and traditional microbial cultures were performed in parallel to compare the differences in pathogen identification. Patients were stratified by immune status based on CD4+ T cell counts, and the association between pathogen profiles and immunodeficiency severity was analyzed. mNGS demonstrated a significantly higher pathogen detection sensitivity (98.0%) compared to traditional cultures (32.1%). The spectrum of pathogens detected by mNGS and culture methods differed significantly. mNGS identified 123 pathogenic microorganisms, whereas cultures detected only 17. mNGS detected additional pathogens, including viruses (e.g., Epstein-Barr virus and cytomegalovirus) and fastidious microorganisms (e.g., Pneumocystis jirovecii). Furthermore, mNGS revealed a significant correlation between PLWH-associated immunodeficiency and pathogen profiles. The diversity of pathogens, particularly fungi and viruses, increased with declining CD4+ T cell counts (p < 0.05). mNGS comprehensively characterizes the complex pathogen spectrum in PLWH-associated pulmonary infections, significantly enhancing detection sensitivity for mixed and fastidious infections, thereby guiding targeted anti-infective therapy. Immunosuppression severity strongly correlates with opportunistic pathogen profiles and the risk of specific pathogen detection, highlighting the importance of immune status-guided clinical strategies. mNGS serves as a valuable adjunct to conventional diagnostic methods, enhancing the detection and prognostic assessment of infectious complications in PLWH.